{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:23:55Z","timestamp":1788474235879,"version":"build-2803163510"},"reference-count":135,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["23SFRNPCS1067039"],"award-info":[{"award-number":["23SFRNPCS1067039"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["R01HS028822"],"award-info":[{"award-number":["R01HS028822"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["R01DK132403"],"award-info":[{"award-number":["R01DK132403"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiovascular-kidney-metabolic (CKM) syndrome represents a complex interplay of obesity, hypertension, hyperlipidemia, type 2 diabetes mellitus, chronic kidney disease, and cardiovascular disease, driving elevated morbidity and mortality. CKM syndrome encompasses a continuum of interrelated metabolic, renal, and cardiovascular dysfunctions attributed to obesity, impaired glucose regulation, and chronic inflammation. This review synthesizes recent literature on the efficacy of cardiorenal protective medications including sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in CKM syndrome management. Sodium-glucose cotransporter 2 inhibitor agents show promising outcomes, including reduced cardiovascular mortality, hospitalization for heart failure, and adverse kidney events across diverse patient populations, regardless of type 2 diabetes mellitus status. Similarly, glucagon-like peptide-1 receptor agonist agents demonstrate substantial benefits in weight loss, glycemic control, and reduced cardiovascular and kidney events. The review also highlights the necessity of equitable pharmacotherapy distribution to ensure that high-risk populations benefit from these advancements and the need for further precision-based therapeutic frameworks, policy innovations, and tailored interventions focused on CKM syndrome management. Finally, we discuss strategies for translating these findings into practice through an equity-focused lens to advance CKM health.<\/jats:p>","DOI":"10.1210\/clinem\/dgaf295","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:15:50Z","timestamp":1747660550000},"page":"2105-2122","source":"Crossref","is-referenced-by-count":26,"title":["Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era"],"prefix":"10.1210","volume":"110","author":[{"given":"Neal","family":"Pohlman","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, The Ohio State University Wexner Medical Center , Columbus, OH 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prem N","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The Ohio State University Wexner Medical Center , Columbus, OH 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utibe R","family":"Essien","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California , Los Angeles, CA 90095 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmyn J","family":"Tang","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California , Los Angeles, CA 90095 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9169-8261","authenticated-orcid":false,"given":"Joshua J","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The Ohio State University Wexner Medical Center , Columbus, OH 43210 ,","place":["USA"]},{"name":"Division of Endocrinology, Diabetes and Metabolism, The Ohio State University College of Medicine , Columbus, OH 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"1","key":"2026051820015319800_dgaf295-B1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12933-023-01937-x","article-title":"The cardio-renal-metabolic connection: a review of the evidence","volume":"22","author":"Marassi","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"20","key":"2026051820015319800_dgaf295-B2","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"20","key":"2026051820015319800_dgaf295-B3","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"5","key":"2026051820015319800_dgaf295-B4","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the heart failure association of the European Society of Cardiology","volume":"20","author":"Seferovi\u0107","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"48","key":"2026051820015319800_dgaf295-B5","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1093\/eurheartj\/ehy596","article-title":"Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the translational research committee of the heart failure association\u2014European society of cardiology","volume":"39","author":"Maack","year":"2018","journal-title":"Eur Heart J"},{"key":"2026051820015319800_dgaf295-B6","first-page":"13","volume-title":"Chronic Kidney Disease and Type 2 Diabetes","author":"Usman","year":"2021"},{"issue":"7","key":"2026051820015319800_dgaf295-B7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"issue":"11","key":"2026051820015319800_dgaf295-B8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"2026051820015319800_dgaf295-B9","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association\u2019s PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"issue":"15","key":"2026051820015319800_dgaf295-B10","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1016\/j.cell.2024.06.029","article-title":"Diabetes mellitus\u2014progress and opportunities in the evolving epidemic","volume":"187","author":"Abel","year":"2024","journal-title":"Cell"},{"issue":"4","key":"2026051820015319800_dgaf295-B11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ecl.2023.05.001","article-title":"Advancing equity in diabetes prevention, treatment, and outcomes: delivering on our values","volume":"52","author":"Joseph","year":"2023","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"12","key":"2026051820015319800_dgaf295-B12","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jama.2024.18219","article-title":"GLP-1 Medication use for type 2 diabetes has soared","volume":"332","author":"Hegland","year":"2024","journal-title":"JAMA"},{"issue":"12","key":"2026051820015319800_dgaf295-B13","doi-asserted-by":"crossref","first-page":"e214182","DOI":"10.1001\/jamahealthforum.2021.4182","article-title":"Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US","volume":"2","author":"Eberly","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"9","key":"2026051820015319800_dgaf295-B14","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/jama.2022.13885","article-title":"Association of race and ethnicity with prescription of SGLT2 inhibitors and GLP1 receptor agonists among patients with type 2 diabetes in the veterans health administration system","volume":"328","author":"Lamprea-Montealegre","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"2026051820015319800_dgaf295-B15","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jama.2021.24538","article-title":"Reducing health disparities through achieving pharmacoequity\u2014reply","volume":"327","author":"Essien","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"2026051820015319800_dgaf295-B16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1215\/03616878-10041135","article-title":"Pursuing pharmacoequity: determinants, drivers, and pathways to progress","volume":"47","author":"Chalasani","year":"2022","journal-title":"J Health Polit Policy Law"},{"issue":"2","key":"2026051820015319800_dgaf295-B17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diab Vasc Dis Res"},{"issue":"4","key":"2026051820015319800_dgaf295-B18","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/jdi.12625","article-title":"Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: a meta-analysis","volume":"8","author":"Cai","year":"2017","journal-title":"J Diabetes Investig"},{"issue":"8","key":"2026051820015319800_dgaf295-B19","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/dom.14400","article-title":"Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: the DISCOVER study","volume":"23","author":"Khunti","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2026051820015319800_dgaf295-B20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13098-023-01092-z","article-title":"Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis","volume":"15","author":"Zhang","year":"2023","journal-title":"Diabetol Metab Syndr"},{"issue":"8","key":"2026051820015319800_dgaf295-B21","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41440-021-00665-7","article-title":"Hypertension in diabetes care: emerging roles of recent hypoglycemic agents","volume":"44","author":"Tanaka","year":"2021","journal-title":"Hypertens Res"},{"issue":"18","key":"2026051820015319800_dgaf295-B22","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","article-title":"Twenty-four-hour blood pressure-lowering effect of a sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study","volume":"139","author":"Kario","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"2026051820015319800_dgaf295-B23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes Mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"issue":"24","key":"2026051820015319800_dgaf295-B24","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMe1904740","article-title":"Clinical credence\u2014SGLT2 inhibitors, diabetes, and chronic kidney disease","volume":"380","author":"Ingelfinger","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"2026051820015319800_dgaf295-B25","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2215\/CJN.11480821","article-title":"SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function","volume":"17","author":"Suijk","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2026051820015319800_dgaf295-B26","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jacc.2023.10.030","article-title":"Hyperuricemia and gout reduction by SGLT2 inhibitors in diabetes and heart failure: JACC review topic of the week","volume":"83","author":"Packer","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026051820015319800_dgaf295-B27","doi-asserted-by":"crossref","first-page":"101549","DOI":"10.1016\/j.molmet.2022.101549","article-title":"Cardiovascular protection by SGLT2 inhibitors\u2014do anti-inflammatory mechanisms play a role?","volume":"64","author":"Elrakaybi","year":"2022","journal-title":"Mol Metab"},{"issue":"17","key":"2026051820015319800_dgaf295-B28","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.3390\/ijerph20176671","article-title":"Immunomodulatory effects of SGLT2 inhibitors\u2014targeting inflammation and oxidative stress in aging","volume":"20","author":"Sch\u00f6nberger","year":"2023","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"2026051820015319800_dgaf295-B29","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/jcp.26760","article-title":"Sodium-glucose cotransporter inhibitors and oxidative stress: an update","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J Cell Physiol"},{"issue":"18","key":"2026051820015319800_dgaf295-B30","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"issue":"22","key":"2026051820015319800_dgaf295-B31","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"2026051820015319800_dgaf295-B32","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(20)30344-2","article-title":"Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial","volume":"8","author":"McGuire","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2026051820015319800_dgaf295-B33","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12933-020-01174-6","article-title":"Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial","volume":"19","author":"Ferreira","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"2026051820015319800_dgaf295-B34","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/dom.13938","article-title":"Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?","volume":"22","author":"Inzucchi","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2026051820015319800_dgaf295-B35","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1210\/clinem\/dgaa321","article-title":"Cardiovascular benefit of empagliflozin across the spectrum of cardiovascular risk factor control in the EMPA-REG OUTCOME trial","volume":"105","author":"Inzucchi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026051820015319800_dgaf295-B36","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1007\/s00125-018-4630-2","article-title":"Empagliflozin in women with type 2 diabetes and cardiovascular disease\u2014an analysis of EMPA-REG OUTCOME\u00ae","volume":"61","author":"Zinman","year":"2018","journal-title":"Diabetologia"},{"issue":"6","key":"2026051820015319800_dgaf295-B37","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/ageing\/afz096","article-title":"Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME\u00ae trial","volume":"48","author":"Monteiro","year":"2019","journal-title":"Age Ageing"},{"issue":"8","key":"2026051820015319800_dgaf295-B38","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1007\/s00125-018-4644-9","article-title":"Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME\u00ae randomised trial","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"issue":"9","key":"2026051820015319800_dgaf295-B39","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/HJH.0000000000002492","article-title":"Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME","volume":"38","author":"B\u00f6hm","year":"2020","journal-title":"J Hypertens"},{"issue":"19","key":"2026051820015319800_dgaf295-B40","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"issue":"5","key":"2026051820015319800_dgaf295-B41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/eurheartj\/ehx511","article-title":"Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME\u00ae trial","volume":"39","author":"Fitchett","year":"2018","journal-title":"Eur Heart J"},{"issue":"11","key":"2026051820015319800_dgaf295-B42","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1161\/CIRCULATIONAHA.118.038339","article-title":"Empagliflozin is associated with a lower risk of post-acute heart failure rehospitalization and mortality","volume":"139","author":"Savarese","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"2026051820015319800_dgaf295-B43","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2026051820015319800_dgaf295-B44","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program","volume":"138","author":"R\u00e5dholm","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"2026051820015319800_dgaf295-B45","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (canagliflozin cardiovascular assessment study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"2026051820015319800_dgaf295-B46","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"2026051820015319800_dgaf295-B47","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction","volume":"139","author":"Furtado","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"2026051820015319800_dgaf295-B48","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ejhf.2073","article-title":"Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58","volume":"23","author":"Zelniker","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"2026051820015319800_dgaf295-B49","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"2026051820015319800_dgaf295-B50","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/dom.14011","article-title":"Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: analysis from the DECLARE-TIMI 58 trial","volume":"22","author":"Bajaj","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"2026051820015319800_dgaf295-B51","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"2026051820015319800_dgaf295-B52","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2337\/dc19-1476","article-title":"Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE\u2013TIMI 58 study","volume":"43","author":"Cahn","year":"2020","journal-title":"Diabetes Care"},{"issue":"1","key":"2026051820015319800_dgaf295-B53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/dom.14179","article-title":"Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: post hoc analyses from DECLARE-TIMI 58","volume":"23","author":"Cahn","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2026051820015319800_dgaf295-B54","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s00125-021-05399-2","article-title":"The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus","volume":"64","author":"O\u2019Donoghue","year":"2021","journal-title":"Diabetologia"},{"issue":"15","key":"2026051820015319800_dgaf295-B55","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"2026051820015319800_dgaf295-B56","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","article-title":"Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial","volume":"142","author":"Cosentino","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"2026051820015319800_dgaf295-B57","first-page":"335","article-title":"New antidiabetes medications and their cardiovascular and renal benefits","volume":"39","author":"Ferro","year":"2021","journal-title":"Cardiol Clin"},{"issue":"24","key":"2026051820015319800_dgaf295-B58","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"2026051820015319800_dgaf295-B59","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2026051820015319800_dgaf295-B60","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"2026051820015319800_dgaf295-B61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"issue":"21","key":"2026051820015319800_dgaf295-B62","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"2026051820015319800_dgaf295-B63","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2026051820015319800_dgaf295-B64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"2026051820015319800_dgaf295-B65","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"2026051820015319800_dgaf295-B66","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"2026051820015319800_dgaf295-B67","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"10365","key":"2026051820015319800_dgaf295-B68","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"2026051820015319800_dgaf295-B69","first-page":"17","article-title":"The cardiovascular benefits associated with the use of sodium-glucose cotransporter 2 inhibitors\u2014real-world data","volume":"14","author":"Gallwitz","year":"2018","journal-title":"Eur Endocrinol"},{"issue":"25","key":"2026051820015319800_dgaf295-B70","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1161\/CIRCULATIONAHA.118.039177","article-title":"Empagliflozin and the risk of heart failure hospitalization in routine clinical care","volume":"139","author":"Patorno","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"2026051820015319800_dgaf295-B71","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2026051820015319800_dgaf295-B72","doi-asserted-by":"crossref","first-page":"101418","DOI":"10.1016\/j.diabet.2022.101418","article-title":"Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study","volume":"49","author":"Karasik","year":"2023","journal-title":"Diabetes Metab"},{"issue":"12","key":"2026051820015319800_dgaf295-B73","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1111\/dom.14162","article-title":"Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence","volume":"22","author":"McEwan","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2026051820015319800_dgaf295-B74","doi-asserted-by":"crossref","first-page":"e2020969","DOI":"10.1001\/jamanetworkopen.2020.20969","article-title":"Coverage, formulary restrictions, and out-of-pocket costs for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in the medicare part D program","volume":"3","author":"Luo","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"12","key":"2026051820015319800_dgaf295-B75","doi-asserted-by":"crossref","first-page":"e214205","DOI":"10.1001\/jamahealthforum.2021.4205","article-title":"Coverage, formulary restrictions, and affordability of sodium-glucose cotransporter 2 inhibitors by US insurance plan types","volume":"2","author":"Tummalapalli","year":"2021","journal-title":"JAMA Health Forum"},{"key":"2026051820015319800_dgaf295-B76","first-page":"100759","article-title":"Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes","volume":"34","author":"Rodriguez","year":"2024","journal-title":"Lancet Reg Health Am"},{"key":"2026051820015319800_dgaf295-B77","doi-asserted-by":"crossref","first-page":"100370","DOI":"10.1016\/j.ajpc.2022.100370","article-title":"County-level variation in cardioprotective antihyperglycemic prescribing among medicare beneficiaries","volume":"11","author":"Hanna","year":"2022","journal-title":"Am J Prev Cardiol"},{"issue":"1","key":"2026051820015319800_dgaf295-B78","doi-asserted-by":"crossref","first-page":"100564","DOI":"10.1016\/j.xkme.2022.100564","article-title":"Disparities in SGLT2 inhibitor or glucagon-like peptide 1 receptor agonist initiation among medicare-insured adults with CKD in the United States","volume":"5","author":"Zhao","year":"2023","journal-title":"Kidney Med"},{"issue":"4","key":"2026051820015319800_dgaf295-B79","doi-asserted-by":"crossref","first-page":"e216139","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic Status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2026051820015319800_dgaf295-B80","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.2337\/dc21-1800","article-title":"Socioeconomic factors play a more important role than clinical needs in the use of SGLT2 inhibitors and GLP-1 receptor agonists in people with type 2 diabetes","volume":"45","author":"Shao","year":"2022","journal-title":"Diabetes Care"},{"issue":"7","key":"2026051820015319800_dgaf295-B81","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2337\/dc21-1178","article-title":"Diabetes care among older adults enrolled in medicare advantage versus traditional medicare fee-for-service plans: the diabetes collaborative registry","volume":"45","author":"Essien","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"2026051820015319800_dgaf295-B82","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.metabol.2013.09.010","article-title":"Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells","volume":"63","author":"Lee","year":"2014","journal-title":"Metabolism"},{"issue":"11","key":"2026051820015319800_dgaf295-B83","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","article-title":"Cardiovascular actions of incretin-based therapies","volume":"114","author":"Ussher","year":"2014","journal-title":"Circ Res"},{"issue":"10456","key":"2026051820015319800_dgaf295-B84","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0140-6736(24)01210-8","article-title":"Obesity in adults","volume":"404","author":"Lingvay","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"2026051820015319800_dgaf295-B85","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jama.2024.6586","article-title":"Is weight loss-induced muscle mass loss clinically relevant?","volume":"332","author":"Conte","year":"2024","journal-title":"JAMA"},{"issue":"9","key":"2026051820015319800_dgaf295-B86","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"2026051820015319800_dgaf295-B87","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"2026051820015319800_dgaf295-B88","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10157","key":"2026051820015319800_dgaf295-B89","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"10193","key":"2026051820015319800_dgaf295-B90","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"2026051820015319800_dgaf295-B91","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"2026051820015319800_dgaf295-B92","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"13","key":"2026051820015319800_dgaf295-B93","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"2026051820015319800_dgaf295-B94","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"2026051820015319800_dgaf295-B95","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"2026051820015319800_dgaf295-B96","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"2026051820015319800_dgaf295-B97","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/ejhf.2670","article-title":"Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial","volume":"24","author":"Branch","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"2026051820015319800_dgaf295-B98","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"2026051820015319800_dgaf295-B99","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"2026051820015319800_dgaf295-B100","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2026051820015319800_dgaf295-B101","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"2026051820015319800_dgaf295-B102","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.7326\/M24-0019","article-title":"Shifting trends in the indication of glucagon-like peptide-1 receptor agonist prescriptions: a nationwide analysis","volume":"177","author":"Yeo","year":"2024","journal-title":"Ann Intern Med"},{"issue":"18","key":"2026051820015319800_dgaf295-B103","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2021.17764","article-title":"A policy prescription for reducing health disparities\u2014achieving pharmacoequity","volume":"326","author":"Essien","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"2026051820015319800_dgaf295-B104","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"2026051820015319800_dgaf295-B105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"10313","key":"2026051820015319800_dgaf295-B106","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet Lond Engl"},{"issue":"11","key":"2026051820015319800_dgaf295-B107","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2026051820015319800_dgaf295-B108","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051820015319800_dgaf295-B109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am Heart J"},{"issue":"9493","key":"2026051820015319800_dgaf295-B110","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"2026051820015319800_dgaf295-B111","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1161\/01.STR.0000071108.00234.0E","article-title":"Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke","volume":"34","author":"Kernan","year":"2003","journal-title":"Stroke"},{"issue":"14","key":"2026051820015319800_dgaf295-B112","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"2026051820015319800_dgaf295-B113","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jacc.2006.10.077","article-title":"A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York heart association functional class I or II heart failure","volume":"49","author":"Dargie","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"9557","key":"2026051820015319800_dgaf295-B114","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(07)60106-8","article-title":"Adjudication of serious heart failure in patients from PROactive","volume":"369","author":"Ryd\u00e9n","year":"2007","journal-title":"Lancet"},{"issue":"11","key":"2026051820015319800_dgaf295-B115","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","article-title":"Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The pioglitazone 001 study group.","volume":"23","author":"Aronoff","year":"2000","journal-title":"Diabetes Care"},{"issue":"6","key":"2026051820015319800_dgaf295-B116","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/dom.14687","article-title":"Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance","volume":"24","author":"Spence","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2026051820015319800_dgaf295-B117","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"15","key":"2026051820015319800_dgaf295-B118","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"2026051820015319800_dgaf295-B119","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"2026051820015319800_dgaf295-B120","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-8587(24)00309-7","article-title":"Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial","volume":"13","author":"Butt","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"2026051820015319800_dgaf295-B121","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"2026051820015319800_dgaf295-B122","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"2026051820015319800_dgaf295-B123","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for Finerenone\u2019s antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"2026051820015319800_dgaf295-B124","doi-asserted-by":"publisher","first-page":"152","year":"2021","DOI":"10.1093\/eurheartj\/ehaa736"},{"issue":"4","key":"2026051820015319800_dgaf295-B125","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2337\/dc21-1113","article-title":"Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes","volume":"45","author":"Wright","year":"2022","journal-title":"Diabetes Care"},{"issue":"6","key":"2026051820015319800_dgaf295-B126","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"issue":"11","key":"2026051820015319800_dgaf295-B127","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European association for the study of diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"2026051820015319800_dgaf295-B128","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"8","key":"2026051820015319800_dgaf295-B129","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/01410768231198442","article-title":"Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"117","author":"Kunutsor","year":"2024","journal-title":"J R Soc Med"},{"issue":"3","key":"2026051820015319800_dgaf295-B130","doi-asserted-by":"crossref","first-page":"e009099","DOI":"10.1161\/CIRCHEARTFAILURE.121.009099","article-title":"Out-of-pocket costs for SGLT-2 (sodium-glucose transport protein-2) inhibitors in the United States","volume":"15","author":"Aggarwal","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026051820015319800_dgaf295-B131","doi-asserted-by":"publisher","author":"Emmerich","year":"2024","DOI":"10.15620\/cdc\/159281"},{"issue":"10440","key":"2026051820015319800_dgaf295-B132","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","article-title":"Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"403","author":"Brauer","year":"2024","journal-title":"Lancet"},{"key":"2026051820015319800_dgaf295-B133","doi-asserted-by":"crossref","first-page":"100315","DOI":"10.1016\/j.ajpc.2022.100315","article-title":"Improving cardiovascular health in black men through a 24-week community-based team lifestyle change intervention: the black impact pilot study","volume":"9","author":"Joseph","year":"2022","journal-title":"Am J Prev Cardiol"},{"issue":"3","key":"2026051820015319800_dgaf295-B134","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s40471-022-00298-5","article-title":"Community-based participatory research to improve cardiovascular health among US racial and ethnic minority groups","volume":"9","author":"Haynes","year":"2022","journal-title":"Curr Epidemiol Rep"},{"issue":"15","key":"2026051820015319800_dgaf295-B135","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacc.2023.02.002","article-title":"Out-of-pocket drug costs for medicare beneficiaries with cardiovascular risk factors under the inflation reduction act","volume":"81","author":"Narasimmaraj","year":"2023","journal-title":"J Am Coll Cardiol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf295\/63237149\/dgaf295.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/8\/2105\/63237149\/dgaf295.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/8\/2105\/63237149\/dgaf295.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:02:14Z","timestamp":1779148934000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/8\/2105\/8137911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":135,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,5,19]]},"published-print":{"date-parts":[[2025,7,15]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf295","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,5,19]]}}}